SCHEMBL22979567

SCHEMBL22979567

NNC(=O)c1ccc(Br)cc1OC(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
ADRA2A P08913 3/20 0.43
MCHR1 Q99705 3/20 0.43
NPY5R Q15761 2/20 0.43
OGG1 O15527 1/20 0.42
KDM4E B2RXH2 3/20 0.42
GAA P10253 2/20 0.42
ALDH1A1 P00352 2/20 0.42
EPHX2 P34913 1/20 0.42
PTPN1 P18031 1/20 0.41
CTSD P07339 1/20 0.41
KMT2A Q03164 1/20 0.40
KCNK3 O14649 1/20 0.39
KCNK9 Q9NPC2 1/20 0.39
DGAT1 O75907 1/20 0.39
GFER P55789 1/20 0.39
TMPRSS4 Q9NRS4 1/20 0.39
POLB P06746 1/20 0.39
ALPL P05186 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12874087 0.88 OGG1 (0.42) MAOAMAOBOGG1KDM4EGAA
SCHEMBL29646357 0.88 OGG1 (0.42) MAOAMAOBOGG1KDM4EGAA
SCHEMBL22979036 0.83 CTSD (0.45) KDM4EGAAALDH1A1EPHX2CTSD
SCHEMBL4441995 0.83 DGAT1 (0.54) MAOAMAOBADRA2AMCHR1NPY5R
SCHEMBL22979526 0.82 KDM4E (0.57) KDM4EGAAALDH1A1CTSDKMT2A
SCHEMBL3938494 0.81 MAOA (0.48) MAOAMAOBADRA2AMCHR1NPY5R
SCHEMBL516923 0.80 ALPL (0.47) MAOAMAOBADRA2AMCHR1NPY5R
SCHEMBL4338973 0.80 CTSD (0.60) MCHR1OGG1KDM4EGAAALDH1A1
SCHEMBL15884073 0.80 MAOA (0.47) MAOAMAOBADRA2AMCHR1NPY5R
SCHEMBL22978965 0.79 TP53 (0.50) KDM4EGAAALDH1A1CTSDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114466850-B [1,2,4] Triazolo [1,5-C ] quinazolin-5-amine 拜耳股份有限公司 2024-09-10 CN disclosed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
EP-4013508-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES Bayer Aktiengesellschaft (DE) 2022-06-22 EP disclosed
CN-114466850-A [1,2,4] triazolo [1,5-C ] quinazolin-5-amines 拜耳股份有限公司 2022-05-10 CN disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES AHR, HRH4, HRH1 MAOA 396/4885MAOB 521/4885ADRA2A 207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.